Qsymia vs Zepbound: An Older Combination Pill Against the Newest GLP-1

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited

Key Takeaways

• Qsymia is an oral combination of phentermine (sympathomimetic appetite suppressant) and topiramate (antiepileptic with weight-loss effects), approved in 2012 for chronic weight management
• Zepbound is once-weekly injectable tirzepatide, approved in November 2023, that activates both GIP and GLP-1 receptors to produce substantial weight loss
• On efficacy, Zepbound wins decisively: roughly 22.5 percent weight loss at 15 mg per SURMOUNT-1 versus 10 to 12 percent at top-dose Qsymia per CONQUER
• On cost, Qsymia often wins: generic phentermine plus topiramate filled separately costs $30 to $80 monthly while Zepbound cash prices run $349 to $699
• The choice depends on insurance coverage, pregnancy status, cardiovascular history, tolerance for injections, and how much weight loss is medically needed

Direct answer

Qsymia and Zepbound take fundamentally different approaches to weight loss. Qsymia combines an older appetite suppressant with an antiepileptic medication that has weight-loss effects, taken as a daily pill. Zepbound is a weekly injection that activates two gut hormone receptors and produces approximately twice the average weight loss seen with Qsymia. Zepbound costs more. Qsymia carries a pregnancy risk and a higher cardiovascular caution profile. Insurance coverage, individual medical history, and tolerance for injections drive most decisions between them.

Table of contents

1. The two medications side by side
2. How Qsymia works mechanistically
3. How Zepbound works mechanistically
4. The pivotal trial results compared
5. Side effect profiles
6. Cost breakdown across access paths
7. Contraindications that matter
8. When Qsymia is the better choice
9. When Zepbound is the better choice
10. The contrary view: Qsymia is underrated
11. Decision framework
12. FAQ
13. Sources

The two medications side by side

Feature	Qsymia	Zepbound
Manufacturer	Vivus (now under various ownership)	Eli Lilly and Company
Active ingredients	Phentermine + topiramate extended-release	Tirzepatide
FDA approval year	2012	2023
Route	Oral capsule, once daily in morning	Subcutaneous injection, once weekly
Approved indication	Chronic weight management, BMI 30+ or BMI 27+ with comorbidities	Chronic weight management, same BMI criteria
Mean weight loss at top dose	Approximately 10 to 12% over 56 weeks (CONQUER)	Approximately 22.5% over 72 weeks at 15 mg (SURMOUNT-1)
Typical cost (cash, monthly)	$200 to $300 brand, $30 to $80 if filled as separate generics	$349 to $699 via LillyDirect; higher at retail pharmacy
Pregnancy	Contraindicated, REMS program with monthly pregnancy testing	Avoid; discontinue 2 months before planned pregnancy
DEA schedule	Schedule IV (phentermine)	Not scheduled

The medications occupy different parts of the obesity treatment landscape. Qsymia is a 2012-era combination of older active ingredients. Zepbound is the highest-efficacy weight-loss medication currently approved. They are not redundant options.

How Qsymia works mechanistically

Qsymia combines two active ingredients with different mechanisms:

Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating norepinephrine release in the hypothalamus. It also produces mild dopamine and serotonin effects. The pharmacology is similar to amphetamine, though phentermine is less potent and not a controlled substance in the same way (it is Schedule IV). Phentermine has been used for weight loss since the 1950s.

Phentermine's primary effect on appetite is hypothalamic. Stimulation of the lateral hypothalamus and reduction of feeding behavior produce reduced caloric intake. Secondary cardiovascular effects (increased heart rate, modest blood pressure elevation) result from the sympathomimetic activity.

Topiramate is an antiepileptic medication originally approved in 1996 for seizure disorders and later for migraine prevention. Its weight-loss effects were observed as a side effect in epilepsy patients and led to systematic study for obesity. The mechanism is multifactorial and not fully understood, but includes:

• Modulation of GABA receptors (inhibitory neurotransmission)
• Blockade of voltage-gated sodium and calcium channels
• Inhibition of carbonic anhydrase
• Possible effects on taste perception (some patients report food tasting different)

The combination produces additive effects on appetite, satiety, and energy intake. The Qsymia formulation is designed to deliver phentermine immediately and topiramate in an extended-release format, balancing tolerability with sustained action.

How Zepbound works mechanistically

Tirzepatide is a single molecule that activates two receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Both are gut-derived hormones involved in glucose regulation and satiety.

The effects:

• GLP-1 effects: Glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite suppression via hypothalamic POMC neurons.
• GIP effects: Complementary insulin secretion in beta cells, potentially additional appetite suppression, and effects on adipose tissue lipid handling. The GIP component contribution to weight loss specifically is debated but appears meaningful based on the comparison between tirzepatide and pure GLP-1 agonists.

The result is a medication that produces approximately 50% greater weight loss than the most effective pure GLP-1 agonists (semaglutide) in head-to-head data. The SURMOUNT-1 trial established the magnitude of effect.

The mechanism differences from Qsymia matter for tolerability and contraindications. Tirzepatide does not produce the cardiovascular stimulation of phentermine. It does produce gastrointestinal effects (nausea, vomiting, diarrhea) that phentermine doesn't typically cause. It carries different safety considerations for pregnancy, gastric procedures, and pancreatitis history.

The pivotal trial results compared

The Qsymia approval was based on three trials: EQUIP, CONQUER, and SEQUEL.

• EQUIP: 1,267 adults with BMI ≥35, 56 weeks. Mean weight loss 10.9% at top dose vs 1.6% on placebo.
• CONQUER: 2,487 adults with BMI 27-45 and comorbidities, 56 weeks. Mean weight loss 9.8% at top dose vs 1.2% on placebo.
• SEQUEL: 675 patients from CONQUER extended to 108 weeks. Continued weight loss maintained.

The Zepbound approval was based on the SURMOUNT program:

• SURMOUNT-1 (Jastreboff et al., NEJM 2022): 2,539 adults with obesity, 72 weeks. Mean weight loss 22.5% at 15 mg, 19.5% at 10 mg, 15.0% at 5 mg, vs 3.1% on placebo.
• SURMOUNT-2: Patients with type 2 diabetes, similar magnitude.
• SURMOUNT-3: Lifestyle-induced weight loss followed by tirzepatide. Total reduction approximately 26%.
• SURMOUNT-4 (Aronne et al., JAMA 2024): Maintenance vs withdrawal. Patients who continued maintained loss; those switched to placebo regained 14 percentage points.

The head-to-head comparison favors Zepbound on magnitude. A patient who achieves the trial average loses roughly twice as much weight on Zepbound as on Qsymia. The proportion of patients achieving 10% or 15% weight loss is also higher with Zepbound.

What the trials don't directly compare: durability, real-world adherence, and patient acceptability. Qsymia has the advantage of decades of accumulated clinical experience. Zepbound has the advantage of larger effect sizes.

Side effect profiles

The medications produce different side effect patterns because the mechanisms differ:

Qsymia common side effects (from CONQUER and EQUIP):

• Paresthesia (tingling in extremities, often described as "fizzing") - 19.9% at top dose
• Dry mouth - 19.1%
• Constipation - 16.1%
• Dysgeusia (altered taste, especially carbonated beverages) - 9.4%
• Insomnia - 9.4%
• Dizziness - 8.6%
• Cognitive effects (word-finding difficulty, concentration problems) - 7.6%
• Elevated heart rate - mean increase 1.6 beats per minute

Zepbound common side effects (from SURMOUNT-1):

• Nausea - approximately 33% (peak during titration)
• Diarrhea - approximately 19%
• Vomiting - approximately 14%
• Constipation - approximately 12%
• Abdominal pain - approximately 11%
• Dyspepsia - approximately 9%
• Injection site reactions - approximately 5%
• Fatigue - approximately 7%

The patterns are distinct. Qsymia patients tend to describe a stimulant-like profile with cognitive and cardiovascular caution. Zepbound patients tend to describe a gastrointestinal profile with appetite suppression dominant. Tolerance preferences differ widely between patients.

Serious adverse events for Qsymia include risk of metabolic acidosis (from topiramate), kidney stones, mood changes including suicidal ideation, and cardiovascular events related to phentermine. Serious adverse events for Zepbound include pancreatitis, gallbladder disease, kidney injury from severe GI symptoms, and theoretical thyroid C-cell tumor risk (based on rodent data; not seen in human trials).

Cost breakdown across access paths

Pricing varies dramatically by source. Here's what cash-pay patients pay across typical paths as of May 2026:

Path	Qsymia monthly cost	Zepbound monthly cost
Brand at retail pharmacy, no insurance	$200 to $300	$1,059 (10 mg pen)
Brand with manufacturer savings card (commercially insured)	$98 first month, then variable	$25 with Lilly card
Generic separates (phentermine + topiramate filled separately)	$30 to $80	Not available (no generic)
LillyDirect vials	Not applicable	$349 to $699 depending on dose
Compounded version	Phentermine alone compounded; full Qsymia formulation not standard	Compounded tirzepatide via 503A pharmacy, $250 to $450 monthly typical
With commercial insurance coverage	Often $30 to $80 copay; broadly covered on older formularies	Coverage rare for weight loss; better for diabetes off-label

The cheapest path to Qsymia's active ingredients is filling phentermine and topiramate separately as generics, which clinicians can do off-label. This isn't technically Qsymia (the brand formulation has the extended-release topiramate component), but many obesity medicine practices use this approach to reduce cost. The clinical effect approximates Qsymia at a fraction of the price.

Zepbound has no generic equivalent. Compounded tirzepatide is the lowest-cost path, but compounded products are not FDA-approved and carry different regulatory status. The Lilly savings card produces dramatic reductions for commercially-insured patients but excludes Medicare, Medicaid, and uninsured patients.

Contraindications that matter

The clinical decision often hinges on contraindications rather than preferences:

Qsymia contraindications include:

• Pregnancy (absolute; topiramate causes oral clefts)
• Glaucoma (topiramate can cause acute angle-closure glaucoma)
• Hyperthyroidism
• Recent or unstable cardiovascular disease
• Concurrent MAOI use (phentermine interaction)
• History of kidney stones (relative; topiramate increases risk)
• Severe hepatic or renal impairment

Zepbound contraindications include:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Prior hypersensitivity to tirzepatide or excipients
• Severe gastroparesis (relative; the slowed emptying could worsen)
• Pregnancy (recommend discontinuation 2 months before planned conception)

The pregnancy difference is significant. Qsymia carries the strictest pregnancy precaution in the obesity drug class because topiramate has documented teratogenic effects. Women of reproductive age on Qsymia enter the iPLEDGE-style REMS program with monthly pregnancy testing requirements. Zepbound's pregnancy precaution is based on general principle (avoid medications without adequate safety data in pregnancy) plus weight-loss-related concerns about pregnancy, not on documented teratogenic effects.

The cardiovascular profiles also differ. Qsymia's phentermine component can elevate blood pressure and heart rate, which matters for patients with cardiovascular disease. Zepbound was shown in SELECT-style cardiovascular outcomes data (for semaglutide) to reduce cardiovascular events; tirzepatide is still being studied for cardiovascular outcomes (the SURPASS-CVOT trial), with preliminary data supportive but not yet conclusive.

When Qsymia is the better choice

Qsymia is the right choice when:

• Cost is a primary barrier and the patient can use generic phentermine plus topiramate at low cost
• The patient prefers oral medication over injection
• The patient has migraine or seizure history where topiramate offers dual benefit
• Insurance covers Qsymia but not Zepbound (more common on older formularies)
• The patient has tolerated previous phentermine courses well
• Weight loss goals are in the moderate range (10 to 15% body weight) rather than transformative
• The patient is not in reproductive years or has reliable contraception in place

Qsymia is not obsolete. It is a legitimate option that produces meaningful weight loss in many patients. The 9.8 to 10.9% mean weight loss in CONQUER and EQUIP represents real clinical benefit for cardiovascular risk reduction, glycemic improvement, and quality of life. The medication has been used for over a decade with a well-characterized safety profile.

When Zepbound is the better choice

Zepbound is the right choice when:

• The patient needs larger magnitude weight loss (15%+ body weight)
• Cardiovascular risk is elevated and the GLP-1 mechanism provides additional benefit
• Type 2 diabetes is also present (tirzepatide is also approved as Mounjaro for diabetes)
• The patient has tolerated previous GLP-1 medications well
• Pregnancy is in the future planning horizon (the discontinuation timeline is more straightforward than Qsymia's REMS)
• The patient has migraine or epilepsy and topiramate is contraindicated for those conditions in their case
• Insurance covers Zepbound or the patient can access the Lilly savings card or LillyDirect

The trade-off is injection administration and higher gastrointestinal side effect burden during titration. For patients comfortable with these, the efficacy advantage is substantial.

The contrary view: Qsymia is underrated

The dominant narrative in 2025-2026 obesity medicine treats GLP-1 medications as the standard and older medications as second-tier. This framing is partly justified by efficacy data but understates several Qsymia advantages.

Argument 1: Real-world adherence may favor oral medications.

Weekly injections produce dropout rates of 25 to 40% in real-world data per insurance claims analyses (NEJM 2023 commentary). Oral once-daily medications often have higher adherence rates because of patient comfort and convenience. The 10 to 12% weight loss with high adherence may exceed 22% efficacy with lower adherence in real-world practice.

Argument 2: Cost matters for sustained treatment.

Obesity is a chronic disease requiring chronic treatment. A medication that costs $50 monthly is sustainable indefinitely for many patients. A medication that costs $700 monthly often is not. The pharmacoeconomics favor Qsymia for patients without strong insurance coverage.

Argument 3: The side effect profile is acceptable for many patients.

Many patients prefer mild stimulant effects (Qsymia) to gastrointestinal effects (Zepbound). The CONQUER trial discontinuation rate for adverse events was 19% at top dose. SURMOUNT-1 discontinuation was 6%, but real-world rates are higher. The tolerance comparison is less one-sided than headline data suggest.

Argument 4: Combination flexibility.

Some obesity medicine specialists combine Qsymia with GLP-1 medications in patients who don't respond adequately to monotherapy. The mechanisms are complementary. This combination approach is off-label but represents legitimate clinical practice in academic obesity centers.

Argument 5: Decades of experience.

Phentermine has been used since 1959 and topiramate since 1996. The combination has been used since 2012. Long-term safety data extend further than any GLP-1 medication. For risk-averse patients, this matters.

These arguments don't make Qsymia equivalent to Zepbound. They argue that the choice is more nuanced than "newer drug wins."

Decision framework

If cost is your primary constraint: Generic phentermine plus topiramate (filled separately, often under $100 monthly) is a strong starting point. Trial response over 12 to 16 weeks and reassess.

If you need transformative weight loss (20%+): Zepbound is the medication with evidence at that magnitude. Plan for cost and injection logistics.

If you're in reproductive years and pregnancy is possible: Both medications require contraception. Qsymia's REMS program is more burdensome. Zepbound has clearer discontinuation timing for pregnancy planning.

If you have cardiovascular disease: Lean toward Zepbound. The phentermine component of Qsymia adds cardiovascular load; tirzepatide does not.

If you have type 2 diabetes: Zepbound or tirzepatide as Mounjaro provides dual benefit. Qsymia does not improve glycemia substantially.

If you have migraine or seizures: Topiramate (Qsymia component) can address both. This is a unique advantage of the combination.

If you can't tolerate injections: Qsymia. Oral administration is the deciding factor for some patients.

FAQ

What is Qsymia? Qsymia is a once-daily oral capsule containing phentermine (a sympathomimetic appetite suppressant) and topiramate (an antiepileptic with weight-loss effects). It was FDA-approved in 2012 for chronic weight management in adults with BMI 30+ or BMI 27+ with comorbidities.

What is Zepbound? Zepbound is the brand name for tirzepatide for chronic weight management, a once-weekly subcutaneous injection from Eli Lilly. It activates both GIP and GLP-1 receptors. FDA-approved for obesity in November 2023, it produces approximately 22.5 percent body weight loss at the 15 mg dose in pivotal trials.

Which is more effective, Qsymia or Zepbound? Zepbound produces greater average weight loss. Qsymia's pivotal CONQUER trial showed approximately 10 to 12% over 56 weeks. Zepbound's SURMOUNT-1 trial showed approximately 22.5% at 15 mg over 72 weeks.

Is Qsymia cheaper than Zepbound? Generally yes. Generic phentermine plus topiramate filled separately can run $30 to $80 monthly. Brand Qsymia runs $200 to $300 monthly with manufacturer savings. Zepbound through LillyDirect runs $349 to $699 monthly cash.

What are the side effects of Qsymia? Common side effects include dry mouth, paresthesia (tingling), constipation, insomnia, dizziness, and cognitive effects (word-finding difficulty from topiramate). Cardiovascular effects include elevated heart rate and blood pressure.

Can I take Qsymia and Zepbound together? Combination use is not standard practice and not specifically studied. Some obesity medicine specialists use sequential or combination approaches in selected patients, but this is off-label.

Is Qsymia safe during pregnancy? No. Qsymia is contraindicated in pregnancy. Topiramate is associated with increased risk of oral clefts. The Qsymia REMS program requires monthly pregnancy testing for women of reproductive potential.

How long can you take Qsymia? Qsymia is FDA-approved for chronic weight management without a duration limit, unlike phentermine alone which is approved for 12-week courses. Long-term safety data extend to about 2 years from the SEQUEL extension study.

What is the difference between Qsymia and phentermine alone? Phentermine alone is approved only for short-term use (12 weeks typically). Adding topiramate in the Qsymia formulation provides additional weight-loss effect and changes the regulatory framework to allow long-term use.

Does Qsymia work for everyone? No. Roughly 70% of patients in CONQUER lost at least 5% body weight at the top dose. About 30% lost less than 5%, which is the threshold for clinical response. Non-responders should consider discontinuation per the FDA label.

Is Zepbound better for diabetes than Qsymia? Yes. Tirzepatide (same molecule, marketed as Mounjaro for diabetes) reduces HbA1c by approximately 2 percentage points and improves glycemic control. Qsymia has modest glycemic effects that are mostly secondary to weight loss.

What if I have trouble swallowing capsules? Qsymia capsules can be opened and sprinkled on food. Zepbound is an injection, so swallowing is not relevant. Patients with severe dysphagia may prefer the injection route.

Sources

1. Allison DB et al. Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP). Obesity. 2012;20(2):330-342.
2. Gadde KM et al. Effects of Low-Dose, Controlled-Release Phentermine plus Topiramate Combination on Weight and Associated Comorbidities in Overweight and Obese Adults (CONQUER). The Lancet. 2011;377(9774):1341-1352.
3. Garvey WT et al. Two-Year Sustained Weight Loss and Metabolic Benefits with Controlled-Release Phentermine/Topiramate in Obese and Overweight Adults (SEQUEL). American Journal of Clinical Nutrition. 2012;95(2):297-308.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
5. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.
6. Vivus Pharmaceuticals. Qsymia Prescribing Information. Revised 2023.
7. Eli Lilly and Company. Zepbound Prescribing Information. Revised 2025.
8. U.S. Food and Drug Administration. Qsymia REMS Program. FDA Drug Safety Communications.
9. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism. 2015;100(2):342-362.
10. Bray GA, Heisel WE, Afshin A et al. The Science of Obesity Management: An Endocrine Society Scientific Statement. Endocrine Reviews. 2018;39(2):79-132.
11. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021;385(6):503-515.
12. American Association of Clinical Endocrinologists. Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity. Endocrine Practice. 2016;22 Suppl 3:1-203.
13. Centers for Disease Control and Prevention. Anti-Obesity Medication Use in U.S. Adults: Trends 2015-2024. NCHS Data Brief. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends partners with independent licensed clinicians and 503A compounding pharmacies for compounded GLP-1 medications. We do not prescribe, manufacture, or distribute Qsymia, Zepbound, or generic phentermine and topiramate. Decisions between obesity medications are made by qualified clinicians based on individual patient factors.

Compounded Medication Notice. Compounded tirzepatide referenced in pricing discussion is prepared by state-licensed 503A compounding pharmacies for individual patient prescriptions and is not FDA-approved. Compounded medications are not interchangeable with brand Zepbound, Mounjaro, Wegovy, or Ozempic from a regulatory perspective. Qsymia is not commonly compounded in its full formulation.

Results Disclaimer. Weight loss outcomes cited reflect trial averages and do not predict individual results. Cost figures use published rates as of May 2026 and may change. Insurance coverage varies by plan, geography, and time. Side effect frequencies cited come from pivotal trial data and may differ in real-world practice.

Trademark Notice. Qsymia is a registered trademark held by Vivus or its successor. Zepbound, Mounjaro, and the Lilly savings card are services of Eli Lilly and Company. Phentermine and topiramate are generic medication names. FormBlends is not affiliated with Vivus, Eli Lilly, or the manufacturers of generic versions of these medications.